For instance, DNA-damaging agents resulted in biphasic dose responses and low drug GRADEs in T47D, a luminal estrogen receptor-positive (ER+) breast cancer cell line (GRADE = 5.5; Figure 5D). This evidence concerns the gene ESR1 and breast cancer.